PMID- 15746047
OWN - NLM
STAT- MEDLINE
DCOM- 20050728
LR  - 20220408
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 4
DP  - 2005 Feb 15
TI  - Prognostic effect of epidermal growth factor receptor and EGFRvIII in 
      glioblastoma multiforme patients.
PG  - 1462-6
AB  - PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed in 
      approximately 50% to 60% of glioblastoma multiforme tumors, and the most common 
      EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases. We sought to 
      determine whether glioblastoma multiforme expression of either overexpressed 
      wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall 
      patient survival. EXPERIMENTAL DESIGN: Glioblastoma multiforme patients (n = 196) 
      underwent a > or =95% volumetric tumor resection followed by conformal radiation. 
      Their EGFR and EGFRvIII status was determined by immunohistochemistry and 
      survival analyses were done. RESULTS: In our study of glioblastoma multiforme 
      patients, 46% (n = 91) failed to express EGFR, 54% (n = 105) had overexpression 
      of the wild-type EGFR, and 31% (n = 61) also expressed the EGFRvIII. Patients 
      within groups expressing the EGFR, EGFRvIII, or lacking EGFR expression did not 
      differ in age, sex, Karnofsky performance scale score, extent of tumor resection, 
      or radiation. The median overall survival times for patients with tumors having 
      EGFR expression absent, overexpressed only, or mutant (EGFRvIII) were 0.96, 0.98, 
      and 1.07 years, respectively. However, for patients surviving > or =1 year, these 
      values were 2.03, 2.02, and 1.21 years (P < 0.0001; log-rank test comparing 
      EGFRvIII with all others). This effect remained significant in the multivariate 
      analysis after adjustment for all other cofactors including age and Karnofsky 
      performance scale score (rate ratio 4.34; 95% confidence interval, 2.21-8.51). 
      CONCLUSIONS: Neither the overexpressed wild-type EGFR nor EGFRvIII was an 
      independent predictor of median overall survival in this selected cohort of 
      patients who underwent extensive tumor resection. However, in patients surviving 
      > or =1 year, the expression of EGFRvIII was an independent negative prognostic 
      indicator.
FAU - Heimberger, Amy B
AU  - Heimberger AB
AD  - Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Unit 
      442, 1515 Holcombe Boulevard, Houston, TX 77030, USA. aheimber@mdanderson.org
FAU - Hlatky, Roman
AU  - Hlatky R
FAU - Suki, Dima
AU  - Suki D
FAU - Yang, David
AU  - Yang D
FAU - Weinberg, Jeff
AU  - Weinberg J
FAU - Gilbert, Mark
AU  - Gilbert M
FAU - Sawaya, Raymond
AU  - Sawaya R
FAU - Aldape, Kenneth
AU  - Aldape K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - ErbB Receptors/*analysis
MH  - Female
MH  - Glioblastoma/metabolism/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
EDAT- 2005/03/05 09:00
MHDA- 2005/07/29 09:00
CRDT- 2005/03/05 09:00
PHST- 2005/03/05 09:00 [pubmed]
PHST- 2005/07/29 09:00 [medline]
PHST- 2005/03/05 09:00 [entrez]
AID - 11/4/1462 [pii]
AID - 10.1158/1078-0432.CCR-04-1737 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2005 Feb 15;11(4):1462-6. doi: 10.1158/1078-0432.CCR-04-1737.